Liothyronine Sodium Tablets — Class II drug recall D-0083-2024
Terminated recall by SUN PHARMACEUTICAL INDUSTRIES INC, reported 2023-11-08, distributed nationwide. Failed Impurities/Degradation Specifications.
| Recall number | D-0083-2024 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | SUN PHARMACEUTICAL INDUSTRIES INC, Princeton, NJ, United States |
| Recall initiated | 2023-10-20 |
| Classified | 2023-11-01 |
| Reported by FDA | 2023-11-08 |
| Terminated | 2024-07-25 |
| Distributed | Nationwide (US) |
| Quantity | 7,392 bottles |
| Reason classes | specification failure |
| NDC | 62756-0589, 62756-0589-01, 62756-0589-08, 62756-0589-18, 62756-0589-83, 62756-0589-88, 62756-0590, 62756-0590-01, 62756-0590-08, 62756-0590-18, 62756-0590-83, 62756-0590-88, 62756-0591, 62756-0591-01, 62756-0591-08, 62756-0591-18, 62756-0591-83, 62756-0591-88 |
| Lot numbers | DND0058A |
| Expiration dates | 2023-12 |
Product
Liothyronine Sodium Tablets, USP, 5 mcg, 100-count bottles, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc.Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Industries Ltd. Survey No. 259/15, Dadra-396 191,(U.T. of D & NH), India. NDC 62756-589-88
Reason for recall
Failed Impurities/Degradation Specifications.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0083-2024. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.